Latest News from: Dana-Farber Cancer Institute

Add to Favorites Subscribe Share
newswise-fb-share-

Showing results

110 of 502
Newswise: Dana-Farber Cancer Institute receives $5 million gift to create the Edward P. Evans Center for Myelodysplastic Syndromes
  • Embargo expired:
    17-Sep-2019 8:00 AM EDT

Article ID: 719007

Dana-Farber Cancer Institute receives $5 million gift to create the Edward P. Evans Center for Myelodysplastic Syndromes

Dana-Farber Cancer Institute

A $5 million gift from the Edward P. Evans Foundation will create the Edward P. Evans Center for Myelodysplastic Syndromes (MDS) at Dana-Farber Cancer Institute.

Released:
16-Sep-2019 11:05 AM EDT
Embargo will expire:
24-Sep-2019 8:00 AM EDT
Released to reporters:
12-Sep-2019 3:05 PM EDT

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 24-Sep-2019 8:00 AM EDT

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Article ID: 717655

Dana-Farber Cancer Institute Is Awarded Its Fourth Consecutive Designation as a Magnet® Organization for Excellence in Nursing Practice and Patient Care

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute has been awarded Magnet® status from the American Nurses Credentialing Center (ANCC) for the fourth consecutive time. This prestigious designation recognizes excellence in nursing practice and health care delivery and has been awarded to only 8% percent of hospitals in the United States.

Released:
20-Aug-2019 2:45 PM EDT
Newswise: Exercise associated with benefit to patients with advanced colorectal cancer

Article ID: 717447

Exercise associated with benefit to patients with advanced colorectal cancer

Dana-Farber Cancer Institute

Patients with metastatic colorectal cancer who engaged in moderate exercise while undergoing chemotherapy tended to have delayed progression of their disease and fewer severe side effects from treatment, according to the results of a new study.

Released:
14-Aug-2019 9:50 AM EDT
Newswise: Inherited pancreatic cancer risk mutation identified
  • Embargo expired:
    12-Aug-2019 11:00 AM EDT

Article ID: 717309

Inherited pancreatic cancer risk mutation identified

Dana-Farber Cancer Institute

The discovery of the previously unknown mutation, reported in Nature Genetics by investigators from Dana-Farber/Brigham and Women’s Cancer Center, could lead to routine testing of individuals with a strong family history of pancreatic cancer to determine if they carry the mutation, occurring in the gene known as RABL3.

Released:
12-Aug-2019 8:35 AM EDT
dana-farber-logo.jpg
  • Embargo expired:
    25-Jul-2019 11:00 AM EDT

Article ID: 716238

New AI tool developed by Dana-Farber identifies cancer outcomes using radiology reports

Dana-Farber Cancer Institute

Scientists at Dana-Farber Cancer Institute have demonstrated that an artificial intelligence tool can perform as well as human reviewers – and much more rapidly - in extracting clinical information regarding changes in tumors from unstructured radiology reports for patients with lung cancer.

Released:
23-Jul-2019 11:05 AM EDT

Research Results

Channels:

All Journal News, Artificial Intelligence, Cancer, JAMA

Languages:

English

Newswise: Discovery of pancreatic neuroendocrine subtypes could help predict likelihood of recurrence

Article ID: 715339

Discovery of pancreatic neuroendocrine subtypes could help predict likelihood of recurrence

Dana-Farber Cancer Institute

Researchers have discovered two distinct subtypes of pancreatic neuroendocrine tumors – known as pNETs – that have dramatically different risks of recurrence following surgical treatment [or surgery]. The finding could yield predictive tests, ease anxiety in patients whose tumors are found to be unlikely to recur, while focusing vigilant follow-up monitoring on patients with pNETs having a higher rate of recurrence.

Released:
3-Jul-2019 1:05 PM EDT
  • Embargo expired:
    1-Jul-2019 9:00 AM EDT

Article ID: 715138

High doses of 60-plus year-old chemotherapy drug found to spur immune system attack on lymphoma

Dana-Farber Cancer Institute

Cyclophosphamide, a mainstay of chemotherapy for many cancers, acts as both chemotherapy and immunotherapy at high doses, study finds

Released:
28-Jun-2019 3:00 PM EDT
dana-farber-logo.jpg

Article ID: 714005

Walking Speed Points to Future Clinical Outcomes for Older Patients with Blood Cancers

Dana-Farber Cancer Institute

Researchers at Dana-Farber Cancer Institute and the VA Boston Healthcare System have uncovered a new vital sign for gauging survival and likelihood of having an unplanned hospitalization in older patients with blood cancers: the speed at which they can walk.In a study published today in the journal Blood, the researchers report that for every 0.

Released:
5-Jun-2019 4:50 PM EDT
  • Embargo expired:
    2-Jun-2019 7:30 AM EDT

Article ID: 713589

Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer

Dana-Farber Cancer Institute

Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer (mHSPC), according to a large study presented by Christopher Sweeney, MBBS of Dana-Farber Cancer Institute's Lank Center for Genitourinary Oncology, during the American Society of Clinical Oncology (ASCO) Annual Meeting.

Released:
2-Jun-2019 6:30 AM EDT

Showing results

110 of 502

Chat now!